Specializing in Vitreoretinal Medicine, Surgery, & Ophthalmic Oncology
Retina Specialists of Tennessee, PLLC distinguishes itself by focusing on the patient first and foremost. Expect the highest quality care delivered by a caring and professional medical doctor. Dr. Gerwin is one of the leading retina specialists in the region--offering both medical and surgical management of eye diseases. At RST, we treat patients with a broad range of retinal disorders and manage complex cases:
RST is committed to providing the medical community and patients in the region with the highest standard of vitreoretinal care. We support the efforts of our local hospitals, charities, and small businesses in this regard.
Residents at the University of Tennessee Erlanger Medical Center spend time at RST as part of their medical education. Dr. Gerwin is committed to training the nation's future doctors.
At Retina Specialists of Tennessee, PLLC, we understand that patients may have other health problems. Working with your other doctors is important for quality care.
At Retina Specialists of Tennessee, PLLC we are committed to research and education. Dr. Gerwin at RST has been involved in over 20 research publications and presentations over the previous decades. He has published in nationally circulated journals and presented at internationally attended research meetings. He has also been involved with national clinical drug trials. He is a reviewer for several top ophthalmology journals including a peer reviewed medical journal focusing on retinal diseases and vitreoretinal surgery. We take pride offering cutting edge diagnostic testing and treatments to our patients.
Dr. Gerwin trained with internationally renowned specialists at some of the highest volume residency and fellowship programs in the United States. He served as an instructor at the nation's first Level 1 Ocular Trauma Center and is the most experienced retina surgeon based in Chattanooga whose retina training was AUPO certified. Dr. Gerwin regularly attends international meetings on new developments in retina and ocular oncology. He continues to serve on the American Academy of Ophthalmology's 2018 Executive Program Committee and also serves on the advisory board of a leading cancer genomics research company. He is proficient in managing complicated ophthalmic disorders. Feel free to discuss the latest research and clinical trials with him.